Latest Articles
-
Abbott’s Humira, Androgel and Nutritional Business Lift Results
Abbott Labs (NYSE:ABT) reported its Q4 results on Wednesday, which topped market expectations on strong growth registered by the auto-immune disease drug, Humira. The performance of research-based proprietary drugs, which are now a part of AbbVie...
-
Why Dr. Oz’s Endorsement Of ChromaDex’s Product Is Huge
Submitted by Gould Partners as part of our contributors program . In late August 2012, Gould Partners issued a “strong buy” recommendation on ChromaDex (CDXC) . At the time, we encouraged investors to purchase shares based on a belie...
-
Abbott Earnings Preview: What We Are Watching
Abbott Labs (NYSE:ABT) is set to announce its Q4 results on January 23. It will be diversified healthcare company’s last quarterly and annual earnings, which will include the performance of research-based proprietary drugs since its split e...
-
Anything For A Buck: Jim Letourneau Looks To Canadian Biotech for Opportunity
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by Daniel Levy of The Life Sciences Report (1/17/13) To avoid some of the “dysfunctional excess” of the energy and mining sec...
-
Weekly Healthcare Notes: Pfizer, Abbott Labs, Merck & JNJ
The past week saw a handful of events for the healthcare sector. First, Pfizer (NYSE:PFE) received the much awaited European approval for expanded use of its blockbuster vaccine Prevenar 13 in children and adolescents aged 6 to 17 years. Pfizer&#...
-
Josh Levine Names Three Biotech Game-Changers
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (1/3/13) Micro-cap biotechs must have creative, adaptive management first and foremost, say...
-
After Eventful Year How Will Abbott Fare In 2013?
As we roll into the new year, we take a look at the pharmaceutical companies under our coverage following an eventful year marked by major patent expiries. However 2012 has been a great year for drug makers as they witnessed sharp run up in their...
-
Weekly Healthcare Note: Pfizer, JNJ, Abbott Labs & UnitedHealth
The past week was handful of events for the healthcare sector. First, Pfizer (NYSE:PFE) received much awaited FDA approval for its blockbuster potential blood thinner drug, Eliquis. Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) followe...
-
ChromaDex Capitalizes on the Health Benefits of pTeroPure (CDXC)
Submitted by Sarah Harris as part of our contributors program . Investors looking for a small company in the early stages of launching a promising product should pay close attention to ChromaDex (CDXC), a natural products and nutraceutical certi...
-
Abbott Labs Snapshot As AbbVie Begins Trading
Abbott Labs ‘ (NYSE:ABT) split into two separately trading companies: one, Abbott Labs, with diversified medical products, and the other, AbbVie, with research-based proprietary pharmaceuticals, will be effective from today on Jan 2 and Ab...
-
Weekly Healthcare Note: Intuitive Surigcal, Abbott Labs, Pfizer & Medtronic
The past week was handful of events for the pharmaceutical sector. Intuitive Surgical (NYSE:ISRG) stock plummeted more than 10% after a scathing report from an influential short selling research firm Citron Research. Meanwhile, Abbott Labs (NYSE:...
-
Abbott Patent Cliff: A Look At The Lipid Regulators Division
While the pharmaceutical companies witness patent approvals and expirations on an ongoing basis, this decade presents a significant challenge to them as many of the world’s largest selling drugs are scheduled to lose their patent protection...
-
Abbott: Potential Upside As Humira Competitors Face Setbacks
Abbott Labs (NYSE:ABT) may have breathed a sigh of relief last week as two potential competitors of Humira, the highest-selling drug of Abbott, have hit roadblocks in their quests for a Rheumatoid Arthritis (RA) drug. Eli Lilly unexpectedly decid...
-
My Best Healthcare Stock Picks For 2013 | Last Year’s Picks Gained 31.55%
Submitted by Dividend Yield as part of our contributors program . Last year at this time, I made a screen of some stocks from the healthcare sector with an interesting market valuation, a great past growth performance as well as good earnings ...
-
Weekly Healthcare Summary: Abbott, Pfizer, JNJ, Boston Scientific, Medtronic and Roche Holdings
We plan to release a weekly note on the recent happenings in the healthcare space impacting healthcare companies under our coverage. Below we summarize a few such events related to Abbott Labs (NYSE:ABT), Pfizer (NYSE:PFE), Johnson & Johnson ...
